Evidence map›Paper›PMID 42497279›Full record

ArticleScience advances2026

The melanocytic transcriptomic state is independently associated with poor overall survival in patients with metastatic melanoma.

Ziyin Huang, Kristen E Rhodin, Rami Al-Rohil, Viviana Geron, Arul M Chinnaiyan, Margaret H O'Connor, Christina V Angeles, Smita K Nair, Matthew K Iyer, Georgia M Beasley

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziyin HuangDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0000-5781-7503
Kristen E RhodinDepartment of Surgery, Duke University, Durham, NC, USA.ORCID 0000-0002-3249-5330
Rami Al-RohilDepartment of Dermatology, University North Carolina, at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-9431-0530
Viviana GeronUniversity of Illinois College of Medicine, Chicago, IL, USA.ORCID 0009-0003-2399-4589
Arul M ChinnaiyanDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-9282-3415
Margaret H O'ConnorDepartment of Surgery, Duke University, Durham, NC, USA.ORCID 0000-0001-5127-8545
Christina V AngelesDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6500-9589
Smita K NairDepartment of Surgery, Duke University, Durham, NC, USA.ORCID 0000-0001-7019-1912
Matthew K IyerDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-0217-7390
Georgia M BeasleyDepartment of Surgery, Duke University, Durham, NC, USA.ORCID 0000-0001-6387-9030

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanomas display distinct transcriptomic states, but it remains unclear how they associate with clinical outcomes. We performed digital spatial RNA profiling (DSP-RNA) of metastatic tumors from patients to investigate how transcriptomic states correlate with melanoma specific survival (MSS) and acral melanoma (AM). We performed DSP-RNA across a tissue microarray constructed from 111 patients with in-transit metastatic melanoma (ITM) diagnosed from 1990 to 2020. Data quality control, noise correction, and normalization yielded high-quality profiles from 105 patients, including 30 (36%) who received immune checkpoint inhibitors and 20 (24%) with AM. We performed principal component (PC) analysis and correlated the results with published gene signatures: The PC1 axis differentiated transitory from undifferentiated melanoma, PC2 reflected immune cell infiltration, PC3 corresponded to stromal cells and neural crest-like melanoma, and PC4 associated with melanocytic melanoma. Across a cohort of treatment-naïve ITM, high expression of the melanocytic state conferred a median MSS difference of 7.72 years (melanocytic "high" = 5.16 years versus "low" = 12.88 years, log-rank

Indexed as

MelanocytesMelanomaSkin NeoplasmsTranscriptomeAgedBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm MetastasisPrincipal Component AnalysisPrognosisBiomarkers, Tumor

Identifiers

PMID42497279
PMCPMC13398476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.